Allison DeAngelis and Andrew Dunn | June 8, 2021, 8:00 AM
- A historic approval of Biogen’s Alzheimer’s drug will have ramifications across the drug industry.
- Analysts expect Aduhelm’s launch to spur more investor interest in Alzheimer’s research.
- Here are the nine companies that stand to benefit the most.
Alzheon is developing an oral treatment and an Alzheimer’s test
The Massachusetts drug company Alzheon has a clear pathway to drug approval after the Aduhelm announcement. Alzheon launched a late-stage trial on June 4 of a drug that targets one form of amyloid beta, known as oligomers.
Read the story here